logo
Lyme disease continues to rise in Quebec and climate change is partially to blame

Lyme disease continues to rise in Quebec and climate change is partially to blame

CBC22-05-2025
Cases of Lyme disease and other tick-borne illnesses have been increasing in Quebec for more than a decade, and experts say climate change is partially to blame.
With increasing temperatures, ticks are becoming more established, especially in southern Quebec, said Kirsten Crandall, a scientific adviser with the Institut national de santé publique du Québec (INSPQ).
And with host animals moving north, be they birds or deer, ticks are covering a broader range, she said. This is especially true for black-legged ticks which can transmit Lyme, she added.
"I think we will definitely be continuing on that rise in the number of different tick-borne diseases," said Crandall. "Lyme disease obviously being the one with the most case numbers."
Lyme disease is caused by a bacterium transmitted by the bite of black-legged ticks. The first symptom is usually a single circular rash.
"Stage 2 and Stage 3 of Lyme disease can affect your heart, you can have neurological symptoms," said Dr. Donald Vinh, an infectious disease specialist at the McGill University Health Centre (MUHC).
"When it comes to those stages there are antibiotics, but they tend to be more intravenous types of antibiotics. So, it's really important to prevent it."
Number of cases rising
The number of declared cases of Lyme disease grew from 127 in 2014 to 653 in 2023. But not all were caught in the province. In 2014, 66 cases were acquired in Quebec. In 2023, that number jumped to 562, or 86 per cent.
Last year, there were 681 cases declared in Quebec, with 568 infections acquired in the province.
As of May 14 of this year, there were 61 reported cases, compared with 68 in the same period last year.
Jade Savage, an entomology professor at Bishop's University in Sherbrooke, said Quebec had an early spring last year, which meant ticks were active sooner. This year, spring has come later — meaning the ticks' activity is later.
Vinh said Quebecers should expect the annual totals to keep rising.
While increased forest excursions and not enough vigilance may play a role, Vinh said another factor is greater awareness among health-care providers that Lyme disease is now endemic in southern Quebec.
The black-legged tick population itself has also been growing.
Last year, the INSPQ mapped the projected spread to help communities and governments plan for the coming decades.
The maps show ticks expanding in areas where they are already found and into northern and eastern regions where they are not usually seen, including Saguenay, the Lower St. Lawrence and the Gaspé.
Crandall said rising temperatures will let tick populations thrive even in places that are typically cooler year-round.
Black-legged ticks can become active after just a few consecutive days above 0 C. Most Lyme infections are acquired in spring and early summer when young ticks are in the nymph stage and are much harder to spot than adult ticks.
Adult ticks are easier to see and are more active in the fall.
Crandall said Lyme disease's major endemic regions are the Outaouais, Montérégie and the Eastern Townships. She said cases are also cropping up along the St. Lawrence River valley.
According to the Health Ministry, there are only four Quebec regions where ticks aren't established: Côte-Nord, Nord-du-Québec, Nunavik and Terres-Cries-de-la-Baie-James. However, the ministry adds, not all established tick populations carry Lyme.
An established tick population is one that returns and continues to thrive after winter.
Less worry, more prevention
While cases acquired in Quebec are rising, Crandall said Lyme disease isn't necessarily something to worry about, but it is something to adapt to. That's why the INSPQ and Health Ministry are working to educate the public about tick bite prevention, Crandall said.
Information about ticks, Lyme disease and tick bite protection can be found on the Health Ministry's website.
Savage launched eTick.ca in 2017 with INSPQ and the Public Health Agency of Canada. The tool, which works as an app or on the website, now serves the entire country, letting people report and identify ticks by uploading a photo. The site also offers advice on preventing bites.
Although 2025 tick reports are off to a slow start because of cooler weather and later spring, she does not expect that to affect the rest of the season. Last year saw a record number of submissions, though that partly reflects the app's growing popularity.
For every 100 submissions, as many as 75 per cent are identified as black-legged ticks. They continue to move into new areas, transported by birds, deer and other hosts, Savage said.
"They keep on expanding and they keep on being more numerous, but that is not necessarily a fully linear process," she explained.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bruce Power gets funding to increase cancer-fighting isotope production
Bruce Power gets funding to increase cancer-fighting isotope production

CTV News

time14 minutes ago

  • CTV News

Bruce Power gets funding to increase cancer-fighting isotope production

Production of medical isotopes at the Bruce Power Nuclear Plant near Kincardine, Ont. is seen in this undated image. (Source: Bruce Power) Domestic supply chains for medical isotope production in Canada has received a boost from the federal government. Announced on Tuesday, the investment of up to $35 million over five years will support the project at the Bruce Power Nuclear Plant facility in Tiverton, Ont. According to the federal government, this next phase will see the installation of a second isotope production system (IPS) at Bruce Power's CANDU Unit 6 reactor, which will allow for a significant increase in the plant's ability to produce the medical isotope lutetium-177, used in targeted cancer therapies. 'Canada is proud to support research and development on medical isotopes... With this investment, we will continue to play a leading role in the global supply of medical isotopes and drive the creation of innovative health care treatments for Canadians,' said Minister of Health, Marjorie Michel. BRUCE POWER - ISOTOPES - AUG 2025 Officials make an announcement at Bruce Power on Aug. 19, 2025. (Scott Miller/CTV News London) Medical isotopes are used by medical professionals to diagnose and treat health conditions such as heart disease and cancer. Medical isotopes are produced using two overarching technologies: nuclear reactors and particle accelerators. There are currently global constraints on the supply of medical isotopes, and according to the government, the CMIE will ensure that Canada remains at the forefront of nuclear medicine innovation.

Swim advisory posted for popular Barrie beach due to high bacteria levels
Swim advisory posted for popular Barrie beach due to high bacteria levels

CTV News

time14 minutes ago

  • CTV News

Swim advisory posted for popular Barrie beach due to high bacteria levels

A swim advisory is in effect at Centennial Beach after water test results raised concerns about safety. The Simcoe Muskoka District Health Unit issued the recommendation based on samples taken on Monday, indicating significant bacteria levels. An advisory is a warning to swimmers, but not a beach closure. Advisories are issued when the bacteria levels exceed those considered safe by the health unit. City staff have posted advisory signs, warning visitors to avoid swimming until further notice. Additional water samples are being taken Monday, and the city says it will provide an update as soon as new results are available from public health officials.

Health Canada approves Ozempic to reduce kidney decline in people with Type 2 diabetes
Health Canada approves Ozempic to reduce kidney decline in people with Type 2 diabetes

Globe and Mail

timean hour ago

  • Globe and Mail

Health Canada approves Ozempic to reduce kidney decline in people with Type 2 diabetes

Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes. Between 30 and 50 per cent of people with Type 2 diabetes develop some form of chronic kidney disease. An international clinical trial, called FLOW, showed the risk of kidneys significantly deteriorating or failing was 24 per cent lower in patients taking Ozempic compared to those taking a placebo injection. The patients taking the drug were also less likely to die from cardiovascular disease – another condition that affects many patients with diabetes. The study, funded by Ozempic manufacturer Novo Nordisk, was peer-reviewed and published in the New England Journal of Medicine last year and contributed to Health Canada's decision. Generic version of Ozempic, Wegovy to launch in Canada by Hims & Hers Dr. David Cherney, a nephrologist at Toronto General Hospital, helped lead the Canadian part of the trial and says the results show it's possible to reduce the loss of kidney function before patients need dialysis or a kidney transplant. 'What my patients are scared of is dialysis – dialysis or a transplant,' said Cherney, who is also a senior scientist at the Toronto General Hospital Research Institute, in an interview. 'I can reasonably reduce that risk and thereby reduce their anxiety and fear of serious, serious complications. Not to mention all the cardiovascular disease, which patients are also extremely afraid of.' Dr. Ehud Ur, an endocrinologist in Vancouver who was not involved in the study, said the results are credible and that Health Canada's approval of Ozempic to help prevent kidney decline is 'great news.' 'The prevention of kidney disease is a very important goal in the management of patients with Type 2 diabetes and this is another tool,' said Ur, who is a professor of endocrinology and metabolism at the University of British Columbia. Ozempic is the brand name of an injectable dose of semaglutide, a glucagon-like peptide-1 (GLP-1) hormone. Ozempic was first approved in Canada as a diabetes medication because it reduces blood sugar. It can also decrease appetite and has been approved as a weight-loss drug for people with obesity at a higher dose under the brand name Wegovy, which is also manufactured by Novo Nordisk. In an e-mail, Health Canada confirmed to The Canadian Press that on Aug. 13, it had approved Ozempic 'to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease.' Glomerular filtration rate is a measure that shows how well the kidneys are filtering out waste and excess water. Semaglutide, or Ozempic, reduces symptoms of feared diabetes complication, study finds Ozempic is the first GLP-1 drug approved in Canada to protect both kidneys and the heart in patients with Type 2 diabetes, said Ur, noting that the cardiovascular benefits of semaglutide have been extensively studied. 'The benefit of Ozempic is that you also get weight loss, which is a very important goal for most people (with Type 2 diabetes). That's a very exciting combination,' he said. Some people experience gastrointestinal side effects when they take Ozempic, Ur said, including nausea, vomiting, constipation and diarrhea. More severe complications can include gall bladder inflammation and pancreatitis, but most side effects are minor, he said. The benefit of slowing or stopping progressive kidney disease in people with diabetes would outweigh the risks of minor side effects, Ur said. The FLOW trial was conducted in 28 countries, including Canada. The researchers randomized 3,533 people with diabetes and chronic kidney disease to either receive Ozempic or a placebo. The study was conducted between 2019 and early 2024. Participants were followed for an average of 3.4 years to monitor for 'major kidney disease events,' including kidney failure leading to dialysis or transplantation, a 50-per-cent reduction in kidney function measured by glomerular filtration rate, or death from kidney-related or cardiovascular causes. The Ozempic or placebo doses were given to participants on top of other medications they were taking, including drugs to control blood pressure and blood sugar. Although reducing blood pressure and blood sugar have beneficial effects for the kidneys, Cherney said Ozempic appeared to have an additional positive impact on kidney function and future research can help pinpoint how that works. 'Another weapon against kidney disease is incredibly powerful. And these medicines will often turn patients around who are doing very poorly because it addresses so many different issues – the kidney, the cardiovascular, the metabolic, and the weight,' said Cherney. Ur said it's possible Ozempic could play a role in reducing inflammation in the kidneys and that might be one explanation for its positive effect. Regardless of the reason for its effectiveness, he said the FLOW trial and Health Canada's approval reinforces the importance of using the drug 'relatively early in the disease process' to minimize kidney damage in people with Type 2 diabetes.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store